HighVista Strategies LLC Invests $470,000 in Disc Medicine, Inc. (NASDAQ:IRON)

HighVista Strategies LLC acquired a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 9,565 shares of the company's stock, valued at approximately $470,000.

Other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Disc Medicine during the 2nd quarter worth about $129,000. Quest Partners LLC bought a new position in shares of Disc Medicine during the 3rd quarter worth about $131,000. Finally, Quantbot Technologies LP bought a new position in shares of Disc Medicine during the 3rd quarter worth about $146,000. Institutional investors own 83.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IRON. Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Wells Fargo & Company began coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a "buy" rating and a $89.00 price objective on the stock. Wedbush reissued an "outperform" rating and issued a $83.00 target price (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Finally, Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 target price on the stock in a research note on Tuesday, November 5th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of "Buy" and an average price target of $85.80.

Disc Medicine Stock Down 0.4 %

NASDAQ:IRON traded down $0.24 on Wednesday, reaching $64.46. The stock had a trading volume of 174,585 shares, compared to its average volume of 349,795. The company has a market capitalization of $1.92 billion, a P/E ratio of -16.51 and a beta of 0.76. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60. The stock has a fifty day moving average price of $54.74 and a 200-day moving average price of $47.94.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15. Sell-side analysts predict that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

Insider Activity at Disc Medicine

In other news, insider William Jacob Savage sold 14,183 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $65.45, for a total transaction of $928,277.35. Following the completion of the sale, the insider now owns 40,405 shares of the company's stock, valued at $2,644,507.25. This represents a 25.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Insiders have sold 32,836 shares of company stock worth $2,038,816 over the last ninety days. Company insiders own 4.24% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.